Luma Vision Raises New Financing for Commercialization of Verafeye Platform

December 18, 2023—Luma Vision announced a total of $22 million in new Series A3 financing. Luma Vision’s Verafeye is an all-in-one four-dimensional imaging and navigation platform with data-driven software applications designed for cardiology.

The company will use the funds to gain FDA clearance, prepare for United States commercialization, and develop the next generations of the Verafeye platform for additional clinical applications in cardiology and beyond.

According to Luma Vision, the Verafeye technology uses the company’s catheter sensor combined with advanced digital imaging and deep learning to provide high-resolution, 360º imagery of the beating heart and surrounding anatomy.

Verafeye can be used with other catheters or systems during cardiac surgery. With multiple applications in one platform, it can provide all of the imaging guidance needed during cardiac surgery in real time, without the need for external systems such as x-ray or CT.

The platform is designed to provide accurate, precise, and comprehensive anatomic data that are required to guide personalized patient therapy across a variety of diseases, such as atrial fibrillation, left atrial appendage closure, and cardiac valve replacement.

“This new technology has the potential to help us deliver more precise therapies for patients suffering from abnormal heart rhythms or structural heart problems,” commented Professor Gabor Szlepaki, MD, in the company’s press release. “This type of medical innovation is essential for the continuous progression of minimally invasive cardiac therapies that can improve patient care.” Prof. Szlepaki is Head of Cardiac Electrophysiology at the Mater Private Hospital Dublin and Centre Clinical lead of the Atrial Fibrillation Institute in Dublin, Ireland.

Luma Vision (formerly known as One Projects Ltd) is a privately held, venture-backed medical device company based in Dublin, Ireland, and Munich, Germany. The company was founded by Chief Executive Officer Fionn Lahart and Chief Technology Officer Christoph Hennersperger. It was originally a spin-out company from BioInnovate Ireland and Trinity College Dublin.

The company advised that the Series A3 financing added three new investors: an undisclosed multinational strategic investor, Atlantic Bridge Growth Fund, and Bayern Kapital. The financing was led by existing investors EQT Lifesciences, ABV Uni Fund. and imec.xpand. The new funding adds to grants won earlier by Luma Vision from the Irish government’s Disruptive Technologies Innovation Fund ($6 million) and the European Innovation Council’s EIC Accelerator ($3 million).